Pulmonary arterial hypertension targeted for new treatment by Sheffield scientists.

[2greys]

Scientists at the University of Sheffield, working in collaboration with drug and vaccine developer Kymab Ltd, Cambridge, have identified a novel antibody that has the potential to become a new treatment for pulmonary arterial hypertension (PAH).

Research published today in Nature Communications (Friday 15 November 2019) from the University’s Department of Infection, Immunity and Cardiovascular Disease shows that treatment with a specific antibody can reverse the process behind the development of PAH, and will now be considered for clinical development.

Pulmonary arterial hypertension or PAH is a rare but fatal disease with the only cure being lung transplantation. It results in high blood within the lungs due to the constriction and overgrowth of the cells within the arteries that supply blood to the lungs.

sheffield.ac.uk/news/nr/new...

[Offcut]

As an IPAH sufferer it is always nice to see a light at the end if the tunnel! Only problem is it takes many years to get all these things passed. One thing that Sheffield do is allow you to take part in the testing of new and old drugs to see if it will help. I also go to Sheffield for my PH treatment so will mention it when I pop up there soon.

Be well

[2greys in reply to Offcut]

You may be able to get it on trial, which can bypass the approval. Something you will have to discuss with your consultant. At least you are now aware of the breakthrough.

[Offcut in reply to 2greys]

A lot of PH medicines is trials we do not have a great deal to lose ?

[mauschen]

Thank you for the information and the link however, if they are still at the animal testing stage, the potential for human benefit appears to be a long way off